Nuria Fabri-Faja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nuria Fabri-Faja has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Maria Carmen Estevez
Nanobiosensors and Bioanalytical Applications Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST and CIBER-BBN, Campus UAB, Bellaterra, Barcelona, Spain
2 shared publications - Olalla Calvo-Lozano
Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, CIBERBBN and BIST, Barcelona 08193, Spain
2 shared publications - Priyanka Dey
University of Portsmouth, UK
2 shared publications Roland A. Terborg
ICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, 08860, Castelldefels (Barcelona), Spain
2 shared publications- Valerio Pruneri
ICFO—Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology 1 , Castelldefels (Barcelona) 08860
2 shared publications Alexander Belushkin
Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015, Switzerland
1 shared publication
Latest Publications
- Open Access
- 1 October 2019
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1077, 232-242
Early sepsis diagnosis via protein and miRNA biomarkers using a novel point-of-care photonic biosensor
- 1 October 2019
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1077, 232-242
Open AccessEarly sepsis diagnosis via protein and miRNA biomarkers using a novel point-of-care photonic biosensor
- Open Access
- 7 December 2018
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 4 (1) , 52-60
Label-free Bacteria Quantification in Blood Plasma by a Bioprinted Microarray Based Interferometric Point-of-Care Device
Existing clinical methods for bacteria detection lack in speed, sensitivity and importantly in Point-of-Care (PoC) applicability. Thus, finding ways to push the sensitivity of clinical PoC biosensing technologies is crucial. Aiming that, we here report a portable PoC device based on Lens-free Interferometric Microscopy (LIM). The device employs high performance nanoplasmonics and custom bioprinted microarrays and is capable of direct label-free bacteria (E. coli) quantification. With only one-step sample handling we offer a sampletodata turnaround time of 40 minutes. Our technology features detection sensitivity of a single bacterial cell both in buffer and diluted blood plasma and is intrinsically limited by the number of cells present in the detection volume. When employed in a hospital setting, the device has enabled accurate categorization of sepsis patients (infectious SIRS) from control groups (healthy individuals and non-infectious SIRS patients) without false positives/negatives. User-friendly on-site bacterial clinical diagnosis can thus become a reality.
- 7 December 2018
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 4 (1) , 52-60
Open AccessLabel-free Bacteria Quantification in Blood Plasma by a Bioprinted Microarray Based Interferometric Point-of-Care Device
Existing clinical methods for bacteria detection lack in speed, sensitivity and importantly in Point-of-Care (PoC) applicability. Thus, finding ways to push the sensitivity of clinical PoC biosensing technologies is crucial. Aiming that, we here report a portable PoC device based on Lens-free Interferometric Microscopy (LIM). The device employs high performance nanoplasmonics and custom bioprinted microarrays and is capable of direct label-free bacteria (E. coli) quantification. With only one-step sample handling we offer a sampletodata turnaround time of 40 minutes. Our technology features detection sensitivity of a single bacterial cell both in buffer and diluted blood plasma and is intrinsically limited by the number of cells present in the detection volume. When employed in a hospital setting, the device has enabled accurate categorization of sepsis patients (infectious SIRS) from control groups (healthy individuals and non-infectious SIRS patients) without false positives/negatives. User-friendly on-site bacterial clinical diagnosis can thus become a reality.